

Hold EUR 6.00 (EUR 5.50) Price EUR 0.62 Upside 867.7 %	Value Indicators: EUR DCF: 5.96	Warburg ESG Risk Score: 3.0 ESG Score (MSCI based): 3.0 Balance Sheet Score: 5.0 Market Liquidity Score: 1.0	Description: Development and distribution of diagnostic products
	Market Snapshot: EUR m Market cap: 2.5 No. of shares (m): 4.1 EV: 2.5 Freefloat MC: 1.8 Ø Trad. Vol. (30d): 0.91 th	Shareholders: Freefloat 71.64 % Deutsche Balaton AG 28.36 %	Key Figures (WRe): 2023e Beta: 2.1 Price / Book: 0.8 x Equity Ratio: 14 %

Conserving cash reach and trying to find a buyer

FY end 31.12. (in EUR m)	Q1 2023 reported	Q1 2022 reported	yoy %
Sales	0.1	0.1	16.5%
EBITDA	-4.4	-2.6	72.0%

Source: Warburg Research, Company data

Epigenomics released Q1 figures that show a company in cash-saving mode. R&D costs decreased to EUR 1.1m in Q1 2023 (Q1 2022: EUR 1.4m), as research and development activities were discontinued as part of the restructuring of the company. SG&A expenses increased from EUR 2m to EUR 4.8m. The increase was caused by costs for the implementation of the restructuring.


As of 31.3.2023, Epigenomics had cash of EUR 6.9m. The company expects that cash to last until mid-2025.

On April 12, 2023 the company announced the resignation of CEO Greg Hamilton effective as of June 30. On May 19, the company also announced the resignation of Executive Board member and CFO Dr. Andrew Lukowiak effective May 31. **The goal of Epigenomics is to utilize its assets (Epi proColon "Next-Gen") for out-licensing and/or asset sale.**

We continue to hold the opinion that Epi proColon "Next-Gen" has shown very encouraging CRC detection rate data, which puts it within striking distance of accessing a potentially larger market and therefore has long-term value. Nevertheless, the financing requirements are considerable. We assume that Epigenomics would need external funds of EUR 130m, which is a significant multiple of the company's current market capitalization. As the materialisation of Epigenomics' business case relies on the company's ability to sell or out-license Epi proColon "Next-Gen", we have decided to develop a scenario that demonstrates the risk-adjusted fair value of Epigenomics asset Epi proColon "Next-Gen" if funding is secured (see next page).

For the moment, we maintain our Hold recommendation.

Changes in Estimates:				Comment on Changes:	
FY End: 31.12. in EUR m	2023e (old)	+ / -	2024e (old)	+ / -	
Sales	0.2	0.0 %	0.2	-50.0 %	■ Estimates adjusted to be more in line with company guidance
EBITDA	-16.3	n.m.	-11.1	n.m.	
EPS	-4.10	n.m.	-2.83	n.m.	



Rel. Performance vs PrimeAll:	
1 month:	2.5 %
6 months:	-62.7 %
Year to date:	-71.8 %
Trailing 12 months:	-70.2 %

Company events:	
15.06.23	AGM
10.08.23	Q2
09.11.23	Q3


FY End: 31.12. in EUR m	CAGR (22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
Sales	-40.9 %	1.1	0.8	6.2	0.5	0.2	0.1	0.1
Change Sales yoy		-26.6 %	-25.2 %	636.7 %	-92.2 %	-58.8 %	-50.0 %	0.0 %
Gross profit margin		77.5 %	82.8 %	97.8 %	75.3 %	50.0 %	0.0 %	0.0 %
EBITDA		-14.2	-11.1	-1.9	-11.3	-6.1	0.3	0.3
Margin		-1258.7 %	-1317.3 %	-31.2 %	-2336.3 %	-3068.8 %	262.4 %	262.4 %
EBIT		-14.7	-11.6	-2.4	-12.1	-6.9	-0.5	-0.5
Margin		-1304.3 %	-1380.9 %	-37.9 %	-2484.7 %	-3450.0 %	-500.0 %	-500.0 %
Net income		-17.0	-11.7	-2.4	-11.9	-7.0	-0.6	-0.6
EPS		-14.61	-8.09	-6.88	-2.90	-1.63	-0.13	-0.13
DPS		0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCFPS		-11.36	-6.63	-0.28	-3.28	-2.25	0.05	0.05
FCF / Market cap		-22.3 %	-14.9 %	-4.5 %	-179.4 %	-362.7 %	7.7 %	7.5 %
EV / Sales		44.5 x	71.8 x	12.0 x	n.a.	13.1 x	n.a.	n.a.
EV / EBITDA		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EV / EBIT		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E adj.		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield		-33.4 %	-18.4 %	-2.6 %	517.3 %	-234.4 %	n.a.	n.a.
Net Debt		-11.0	-3.9	-22.2	-9.6	0.0	-0.2	-0.4
ROCE (NOPAT)		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Guidance:		adj EBITDA EUR -7 - -9m						

Epigenomics model scenario

Epigenomics	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e
Patient population US, in m	103.0	104.1	105.1	106.2	107.2	108.3	109.4	110.5	111.6	112.7	113.8	114.9
- thereof unscreened	50.5	51.0	51.5	52.0	52.5	53.1	53.6	54.1	54.7	55.2	55.8	56.3
- market share ECX	0.0%	0.0%	0.0%	0.1%	0.9%	1.5%	2.0%	2.5%	3.0%	3.3%	3.6%	3.9%
- thereof remaining	52.5	53.1	53.6	54.1	54.7	55.2	55.8	56.3	56.9	57.5	58.0	58.6
- market share ECX	0.0%	0.0%	0.0%	0.1%	0.9%	1.5%	2.0%	2.5%	3.0%	3.3%	3.6%	3.9%
EpiProColon patients	0.0	0.0	0.0	0.1	1.0	1.6	2.2	2.8	3.3	3.7	4.1	4.5
- total market penetration	0.0%	0.0%	0.0%	0.1%	0.9%	1.5%	2.0%	2.5%	3.0%	3.3%	3.6%	3.9%
North America												
Tests sold	0	0	0	53,076	964,922	1,624,285	2,187,371	2,761,555	3,347,005	3,718,523	4,097,136	4,482,949
increase absolute			0	53,076	911,846	659,363	563,085	574,185	585,450	371,518	378,613	385,814
growth y-o-y	nm	nm	nm	nm	1718%	68%	35%	26%	21%	11%	10%	9%
Price per unit sold, USDm	100	100	100	100	100	100	100	100	100	100	100	100
Revenue, USDm	0.0	0.0	0.0	5.3	96.5	162.4	218.7	276.2	334.7	371.9	409.7	448.3
USD/EUR rate	1.06	1.06	1.06	1.06	1.06	1.06	1.06	1.06	1.06	1.06	1.06	1.06
Revenue, EURm	0.0	0.0	0.0	5.0	91.0	153.2	206.4	260.5	315.8	350.8	386.5	422.9
- risk adjustment	100%	100%	100%	100%	80%	80%	80%	80%	80%	80%	80%	80%
Revenue risk adj., EURm	0.0	0.0	0.0	5.0	72.8	122.6	165.1	208.4	252.6	280.6	309.2	338.3
COGS	0.0	0.0	0.0	-1.0	-14.6	-24.5	-24.8	-31.3	-37.9	-42.1	-46.4	-50.8
- in perc. of sales	20%	20%	20%	20%	20%	20%	15%	15%	15%	15%	15%	15%
R&D	-20.0	-25.0	-15.0	-10.0	-5.0	-5.0	-5.0	-5.0	-5.0	-5.0	-5.0	-5.0
- in pct of sales	-24615.4%	-25641.0%	-13377.9%	-194.9%	-5.5%	-3.3%	-2.4%	-1.9%	-1.6%	-1.4%	-1.3%	-1.2%
General and admin	-5.0	-5.0	-5.0	-5.0	-10.9	-18.4	-24.8	-31.3	-37.9	-42.1	-46.4	-50.8
Sales and marketing	-5.0	-5.0	-5.0	-5.0	-10.9	-18.4	-24.8	-31.3	-37.9	-42.1	-46.4	-50.8
- SGA in pct of sales	nm	nm	nm	-199.7%	-30.0%	-30.0%	-30.0%	-30.0%	-30.0%	-30.0%	-30.0%	-30.0%
Other operating result	1.5	-5.0	-5.0	-5.0	-5.0	-9.8	-16.5	-20.8	-25.3	-28.1	-30.9	-33.8
- in pct of sales	nm	nm	nm	-99.9%	-6.9%	-8.0%	-10.0%	-10.0%	-10.0%	-10.0%	-10.0%	-10.0%
EBIT risk adj.	-28.5	-40.0	-30.0	-21.0	26.4	46.5	69.3	88.8	108.7	121.3	134.1	147.3
- margin	-35076.9%	-41025.6%	-26755.9%	-409.2%	36.2%	37.9%	41.9%	42.6%	43.0%	43.2%	43.4%	43.5%
TV growth rate	3%											
TV fair value	194.97											
Discount rate	12.74%											
Sum company fair value (EURm)	377.4											


Source: Warburg Research

Sales development in EUR m




Source: Warburg Research

Tests sold by regions 2024e; in %



Source: Warburg Research

EBIT development in EUR m



Source: Warburg Research


Company Background

- Epigenomics was founded in Berlin in 1998.
- Epigenomics is the innovator of the Septin9 test for the detection of different cancer types.
- The company received FDA-approval for its Septin9 colorectal cancer (CRC) test Epi proColon in April 2016.
- The patent-protected test kit is distributed directly by Epigenomics in Europe and Germany and by partners in North America.

Competitive Quality


- Epi proColon is a convenient and innovative blood test for the early detection of cancer.
- Epigenomics has an early-mover advantage with its blood-based cancer test, which should help raise awareness of Epi proColon and secure high market share once it is included in the national reimbursement list in the US.
- The tests currently available are less convenient (stool-test) and more time-consuming (colonoscopy) than blood tests. Surveys show a high acceptance rate for tests that are easy to perform, like Epi proColon.

EBT development in EUR m




Source: Warburg Research

Sales by regions 2024e; in %



Source: Warburg Research

Net income development in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period			Transitional period										Term. Value												
	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e													
Sales	0.2	0.1	0.1	4.2	30.2	45.3	60.4	70.5	80.5	85.6	90.6	93.3	96.1	3.0 %												
Sales change	-58.8 %	-50.0 %	0.0 %	4132.2 %	613.5 %	50.0 %	33.3 %	16.7 %	14.3 %	6.3 %	5.9 %	3.0 %	3.0 %													
EBIT	-6.9	-0.5	-0.5	-6.5	1.7	5.6	9.5	11.7	13.7	15.1	16.5	17.0	15.1													
EBIT-margin	-3450.0 %	-500.0 %	-500.0 %	-154.2 %	5.5 %	12.3 %	15.8 %	16.6 %	17.1 %	17.7 %	18.2 %	18.2 %	15.7 %													
Tax rate (EBT)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %													
NOPAT	-6.9	-0.5	-0.5	-6.5	1.7	5.6	9.5	11.7	13.7	15.1	16.5	17.0	15.1													
Depreciation in % of Sales	0.8	0.8	0.8	0.1	0.5	0.7	0.8	0.8	0.8	0.9	0.9	0.9	1.0		381.2 %	762.4 %	762.4 %	2.0 %	1.8 %	1.6 %	1.3 %	1.1 %	1.0 %	1.0 %	1.0 %	1.0 %
Changes in provisions	0.0	0.0	0.0	-0.4	0.5	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.1													
Change in Liquidity from - Working Capital	3.4	0.0	0.0	0.8	6.7	3.8	3.8	2.5	2.5	1.3	1.3	0.7	0.7													
- Capex	0.0	0.0	0.0	1.0	3.3	2.7	2.0	1.6	1.4	1.2	1.1	1.0	1.0													
Capex in % of Sales	0.0 %	0.0 %	0.0 %	24.0 %	11.0 %	6.0 %	3.3 %	2.2 %	1.7 %	1.4 %	1.2 %	1.1 %	1.0 %													
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0													
Free Cash Flow (WACC Model)	-9.5	0.3	0.3	-8.7	-7.3	0.1	4.8	8.6	10.8	13.6	15.1	16.2	14.4		11											
PV of FCF	-8.9	0.2	0.2	-5.7	-4.2	0.1	2.2	3.5	3.9	4.3	4.2	4.1	3.2		25											
share of PVs	-26.53 %			48.54 %										77.99 %												

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	15.00 %	Financial Strength	3.00
Cost of debt (after tax)	4.5 %	Liquidity (share)	1.40
Market return	8.25 %	Cyclicality	1.00
Risk free rate	2.75 %	Transparency	2.00
		Others	3.00
WACC	12.74 %	Beta	2.08

Valuation (m)

Present values 2035e	7
Terminal Value	25
Financial liabilities	0
Pension liabilities	1
Hybrid capital	0
Minority interest	0
Market val. of investments	0
Liquidity	10
Equity Value	42
No. of shares (m)	7.0
Value per share (EUR)	5.96

Sensitivity Value per Share (EUR)

Beta	WACC	Terminal Growth							Delta EBIT-margin								
		2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	3.50 %	3.75 %	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp		
2.29	13.7 %	4.86	4.92	4.98	5.04	5.11	5.19	5.26	2.29	13.7 %	4.30	4.55	4.80	5.04	5.29	5.54	5.79
2.19	13.2 %	5.26	5.33	5.40	5.48	5.56	5.64	5.73	2.19	13.2 %	4.69	4.95	5.21	5.48	5.74	6.01	6.27
2.13	13.0 %	5.48	5.55	5.63	5.71	5.80	5.89	5.99	2.13	13.0 %	4.89	5.17	5.44	5.71	5.99	6.26	6.54
2.08	12.7 %	5.71	5.79	5.87	5.96	6.06	6.16	6.26	2.08	12.7 %	5.12	5.40	5.68	5.96	6.25	6.53	6.81
2.03	12.5 %	5.95	6.04	6.13	6.23	6.33	6.44	6.55	2.03	12.5 %	5.35	5.64	5.94	6.23	6.52	6.81	7.11
1.97	12.2 %	6.21	6.30	6.40	6.51	6.62	6.74	6.86	1.97	12.2 %	5.60	5.90	6.20	6.51	6.81	7.11	7.42
1.87	11.7 %	6.77	6.88	7.00	7.12	7.25	7.39	7.54	1.87	11.7 %	6.14	6.47	6.79	7.12	7.45	7.77	8.10

- Sales level in 2030/2031 reflects market share of approx. 3% of unscreened CRC population
- Sales growth assumption of 3% from 2034 onwards reflects potential entry of new techniques or competitors
- EBIT margin of 17.5% in terminal year in line with margin level of established healthcare product companies
- Tax rate at 0% due to taxloss carryforwards
- Dilutive impact of planned mandatory convertible factored in

Valuation	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	6.3 x	16.7 x	4.3 x	0.7 x	0.8 x	1.0 x	1.4 x
Book value per share ex intangibles	0.85	2.53	5.73	1.76	0.05	-0.10	-0.23
EV / Sales	44.5 x	71.8 x	12.0 x	n.a.	13.1 x	n.a.	n.a.
EV / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EV / EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EV / EBIT adj.*	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / FCF	n.a.	n.a.	n.a.	n.a.	n.a.	20.9 x	21.4 x
P / E	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
P / E adj.*	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	-33.4 %	-18.4 %	-2.6 %	517.3 %	-234.4 %	n.a.	n.a.

*Adjustments made for: EBITDA before share-based payment expenses

Consolidated profit and loss

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Sales	1.1	0.8	6.2	0.5	0.2	0.1	0.1
Change Sales yoy	-26.6 %	-25.2 %	636.7 %	-92.2 %	-58.8 %	-50.0 %	0.0 %
COGS	0.3	0.1	0.1	0.1	0.1	0.1	0.1
Gross profit	0.9	0.7	6.1	0.4	0.1	0.0	0.0
Gross margin	77.5 %	82.8 %	97.8 %	75.3 %	50.0 %	0.0 %	0.0 %
Research and development	7.3	3.7	3.1	6.7	4.5	0.5	0.5
Sales and marketing	8.9	7.3	7.5	6.6	2.0	0.8	0.8
Administration expenses	0.0	0.0	0.0	0.0	2.0	0.8	0.8
Other operating expenses	1.8	2.9	1.0	0.9	0.0	0.0	0.0
Other operating income	2.5	1.5	3.2	1.9	1.5	1.5	1.5
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-14.2	-11.1	-1.9	-11.3	-6.1	0.3	0.3
Margin	-1258.7 %	-1317.3 %	-31.2 %	-2336.3 %	-3068.8 %	262.4 %	262.4 %
Depreciation of fixed assets	0.3	0.3	0.3	0.7	0.8	0.8	0.8
EBITA	-14.5	-11.4	-2.3	-12.1	-6.9	-0.5	-0.5
Amortisation of intangible assets	0.2	0.2	0.1	0.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	-14.7	-11.6	-2.4	-12.1	-6.9	-0.5	-0.5
Margin	-1304.3 %	-1380.9 %	-37.9 %	-2484.7 %	-3450.0 %	-500.0 %	-500.0 %
EBIT adj.	-14.7	-11.6	-2.4	-12.1	-6.9	-0.5	-0.5
Interest income	0.2	0.0	0.0	0.1	0.0	0.0	0.0
Interest expenses	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	-14.6	-11.7	-2.4	-12.1	-7.0	-0.6	-0.6
Margin	-1294.8 %	-1385.2 %	-38.8 %	-2495.1 %	-3480.0 %	-560.0 %	-560.0 %
Total taxes	2.5	0.0	0.0	-0.1	0.0	0.0	0.0
Net income from continuing operations	-17.0	-11.7	-2.4	-12.0	-7.0	-0.6	-0.6
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	-17.0	-11.7	-2.4	-11.9	-7.0	-0.6	-0.6
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-17.0	-11.7	-2.4	-11.9	-7.0	-0.6	-0.6
Margin	-1512.9 %	-1387.9 %	-39.1 %	-2449.7 %	-3480.0 %	-560.0 %	-560.0 %
Number of shares, average	1.2	1.4	15.5	4.1	4.3	4.3	4.3
EPS	-14.61	-8.09	-6.88	-2.90	-1.63	-0.13	-0.13
EPS adj.	-14.12	-6.98	-6.88	-2.90	-1.63	-0.13	-0.13

*Adjustments made for: EBITDA before share-based payment expenses


Guidance: adj EBITDA EUR -7 - -9m

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	1381.8 %	1463.7 %	135.8 %	2560.0 %	3500.0 %	500.0 %	500.0 %
Operating Leverage	-0.5 x	0.8 x	-0.1 x	-4.5 x	0.7 x	1.9 x	n.a.
EBITDA / Interest expenses	n.m.	n.m.	n.m.	n.m.	n.m.	4.4 x	4.4 x
Tax rate (EBT)	-16.8 %	-0.2 %	-0.7 %	0.6 %	0.0 %	0.0 %	0.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	26,163	21,590	167,649	14,265	5,882	2,941	2,941

Sales, EBITDA


in EUR m



Source: Warburg Research


Operating Performance

in %



Source: Warburg Research

Performance per Share



Source: Warburg Research


Consolidated balance sheet

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Assets							
Goodwill and other intangible assets	0.3	0.1	0.1	3.0	3.0	3.0	3.0
thereof other intangible assets	0.3	0.1	0.1	3.0	3.0	3.0	3.0
thereof Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property, plant and equipment	1.5	1.2	0.9	2.1	1.3	0.5	-0.2
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	1.9	1.3	1.0	5.0	4.3	3.5	2.7
Inventories	0.3	0.1	0.2	0.1	0.0	0.0	0.0
Accounts receivable	0.1	0.3	0.1	0.1	0.0	0.0	0.0
Liquid assets	11.0	4.5	23.0	10.1	18.5	36.7	54.9
Other short-term assets	0.7	0.6	0.4	0.5	0.5	0.5	0.5
Current assets	12.1	5.5	23.7	10.8	19.1	37.3	55.5
Total Assets	14.0	6.8	24.7	15.9	23.4	40.8	58.2
Liabilities and shareholders' equity							
Subscribed capital	43.5	5.9	15.5	4.1	4.1	4.1	4.1
Capital reserve	69.3	87.4	99.8	102.4	102.4	102.4	102.4
Retained earnings	-102.8	-79.0	-93.2	-84.4	-91.3	-91.9	-92.5
Other equity components	-0.3	-10.4	0.2	-11.9	-11.9	-12.0	-12.0
Shareholders' equity	9.6	3.9	22.3	10.2	3.2	2.6	2.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	9.6	3.9	22.3	10.2	3.2	2.6	2.0
Provisions	1.3	1.4	1.4	1.1	1.1	1.1	1.1
thereof provisions for pensions and similar obligations	0.1	0.6	0.8	0.5	0.5	0.5	0.5
Financial liabilities (total)	0.0	0.0	0.0	0.0	18.0	36.0	54.0
Short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.4	0.6	0.5	3.5	0.0	0.0	0.0
Other liabilities	1.6	0.9	0.4	1.1	1.1	1.1	1.1
Liabilities	4.4	2.9	2.4	5.7	20.2	38.2	56.2
Total liabilities and shareholders' equity	14.0	6.8	24.7	15.9	23.4	40.8	58.2


Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	2.2 x	0.9 x	9.6 x	-0.4 x	0.2 x	0.2 x	-0.4 x
Capital Employed Turnover	-0.8 x	-16.9 x	53.0 x	0.9 x	0.1 x	0.0 x	0.1 x
ROA	-912.1 %	-880.0 %	-252.5 %	-235.9 %	-162.8 %	-15.9 %	-20.4 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
ROE	-120.5 %	-173.2 %	-18.5 %	-73.1 %	-104.0 %	-19.4 %	-24.6 %
Adj. ROE	-120.0 %	-149.4 %	-18.5 %	-73.1 %	-104.0 %	-19.4 %	-24.6 %
Balance sheet quality							
Net Debt	-11.0	-3.9	-22.2	-9.6	0.0	-0.2	-0.4
Net Financial Debt	-11.0	-4.5	-23.0	-10.1	-0.5	-0.7	-0.9
Net Gearing	-113.9 %	-101.3 %	-99.5 %	-94.6 %	-0.8 %	-9.0 %	-21.6 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	0.9	2.6	5.7	2.5	0.8	0.6	0.5
Book value per share ex intangibles	0.9	2.5	5.7	1.8	0.1	-0.1	-0.2


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated cash flow statement

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	-17.0	-11.7	-2.4	-11.9	-7.0	-0.6	-0.6
Depreciation of fixed assets	0.3	0.3	0.3	0.7	0.8	0.8	0.8
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.2	0.2	0.1	0.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	-0.4	0.3	0.2	-0.3	0.0	0.0	0.0
Other non-cash income and expenses	3.2	0.8	-1.3	0.0	0.0	0.0	0.0
Cash Flow before NWC change	-13.6	-10.0	-3.1	-11.5	-6.2	0.2	0.2
Increase / decrease in inventory	0.0	0.2	-0.1	0.1	0.1	0.0	0.0
Increase / decrease in accounts receivable	0.1	-0.2	0.2	0.0	0.1	0.0	0.0
Increase / decrease in accounts payable	0.1	0.4	-0.1	3.0	-3.5	0.0	0.0
Increase / decrease in other working capital positions	-0.1	0.0	-1.3	-3.7	0.0	0.0	0.0
Increase / decrease in working capital (total)	0.1	0.4	-1.3	-0.6	-3.4	0.0	0.0
Net cash provided by operating activities [1]	-13.5	-9.6	-4.4	-12.0	-9.6	0.2	0.2
Investments in intangible assets	0.0	0.0	0.0	-0.5	0.0	0.0	0.0
Investments in property, plant and equipment	-0.1	-1.0	0.0	-0.8	0.0	0.0	0.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.2	0.0	1.0	-0.3	0.0	0.0	0.0
Net cash provided by investing activities [2]	0.0	0.0	1.0	-1.7	0.0	0.0	0.0
Change in financial liabilities	0.0	0.0	0.0	0.0	18.0	18.0	18.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	7.3	3.3	21.9	0.0	0.0	0.0	0.0
Other	-0.2	-0.3	-0.3	-0.4	0.0	0.0	0.0
Net cash provided by financing activities [3]	7.1	3.0	21.6	-0.4	18.0	18.0	18.0
Change in liquid funds [1]+[2]+[3]	-6.3	-6.6	18.2	-14.1	8.4	18.2	18.2
Effects of exchange-rate changes on cash	0.0	0.0	1.1	1.2	0.0	0.0	0.0
Cash and cash equivalent at end of period	10.2	3.6	22.8	10.1	18.5	36.7	54.9


Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	-13.6	-9.6	-4.4	-13.4	-9.6	0.2	0.2
Free Cash Flow / Sales	-1211.4 %	-1138.0 %	-70.8 %	-2764.5 %	-4796.8 %	202.4 %	202.4 %
Free Cash Flow Potential	-16.7	-11.1	-2.0	-11.1	-6.1	n.a.	n.a.
Free Cash Flow / Net Profit	80.1 %	82.0 %	181.2 %	112.9 %	137.8 %	-36.1 %	-36.1 %
Interest Received / Avg. Cash	1.2 %	0.3 %	0.0 %	0.6 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	n.a.	n.a.	n.a.	n.a.	0.7 %	0.2 %	0.1 %
Management of Funds							
Investment ratio	10.8 %	118.8 %	0.0 %	281.4 %	0.0 %	0.0 %	0.0 %
Maint. Capex / Sales	6.7 %	0.0 %	0.0 %	0.0 %	0.0 %	n.a.	n.a.
Capex / Dep	23.8 %	186.9 %	0.0 %	189.6 %	0.0 %	0.0 %	0.0 %
Avg. Working Capital / Sales	-84.9 %	-76.2 %	-4.1 %	-376.3 %	-849.0 %	0.0 %	0.0 %
Trade Debtors / Trade Creditors	6.2 %	39.9 %	14.5 %	2.3 %	n.a.	n.a.	n.a.
Inventory Turnover	0.8 x	1.2 x	0.8 x	2.0 x	n.a.	n.a.	n.a.
Receivables collection period (days)	29	109	4	62	0	0	0
Payables payment period (days)	2,063	1,583	1,350	10,768	0	0	0
Cash conversion cycle (Days)	-1,583	-1,167	-873	-10,519	n.a.	n.a.	n.a.


CAPEX and Cash Flow
in EUR m



Free Cash Flow Generation



Working Capital



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All **data and consensus estimates** have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Epigenomics	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A32VN83.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	159	75
Hold	43	20
Sell	7	3
Rating suspended	3	1
Total	212	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	45	88
Hold	5	10
Sell	0	0
Rating suspended	1	2
Total	51	100

PRICE AND RATING HISTORY EPIGENOMICS AS OF 01.06.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Fabio Hölscher +49 40 309537-240
Automobiles, Car Suppliers fhoelscher@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate, Construction pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Hannes Müller +49 40 309537-255
Software, IT hmueller@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate, Telco sstippig@warburg-research.com

Cansu Tatar +49 40 309537-248
Cap. Goods, Engineering ctatar@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Marc Niemann +49 40 3282-2660
Head of Equity Sales, Germany mniemann@mmwarburg.com

Klaus Schilling +49 69 5050-7400
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Lea Bogdanova +49 69 5050-7411
United Kingdom, Ireland lbogdanova@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom mfritsch@mmwarburg.com

Maximilian Martin +49 69 5050-7413
Austria, Poland mmartin@mmwarburg.com

Christopher Seedorf +49 40 3282-2695
Switzerland cseedorf@mmwarburg.com

Charlotte Wernicke +49 40 3282-2669
Roadshow/Marketing cwernicke@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Marcel Magiera +49 40 3282-2662
Sales Trading mmagiera@mmwarburg.com

Rico Müller +49 40 3282-2685
Sales Trading rmueller@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Jan-Philip Schmidt +49 40 3282-2682
Sales Trading jschmidt@mmwarburg.com

Sebastian Schulz +49 40 3282-2631
Sales Trading sschulz@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Sales Trading jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

Refinitiv www.refinitiv.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com